Ipilimumab Antibody

IgG1-kappa

PBS buffer, pH 7.5

> 95%

2.27 mg/ml (lot specific)

Specificty Target Names (Species): CTLA4/CD152 [Homo Sapiens]

Store at 4°C for 1-2 weeks
Store at -20°C for 12 months
Store at -80°C for long term storage.
Use a manual defrost freezer and avoid repeated freeze/thaw cycles.

148000.00Da

477202-00-9

Human (Homo Sapiens)

Ipilimumab (anti-CTLA-4), is a fully humanized IgG1k monoclonal antibody produced by recombinant DNA technology in a CHO mammalian cell expression system, binding with high affinity to the extracellular domain of human (and Cynomolgus monkey) CTLA-4, and acting as an inhibitor of its complex functions. This essentially results in T-cell activation and proliferation, and in lymphocyte infiltration leading to tumor cell death. However, the enhancement of T effector cell function, combined with the inhibition of CD4+ Treg and CD8+ suppressive cell types, are considered essential for mediating the full therapeutic effects of ipilimumab. Ipilimumab can improve ATC proliferation, enhance the BiAb-mediated tumor-specific cytotoxicity, and increase cytokine synthesis, while it attenuates Treg activity as shown by decreased level of IL-10 secretion and reduced Treg population. Ipilimumab and nivolumab treatments could collaboratively enhance effector and memory T cell responses without inappropriately activating naive T cells.

Manufactured in an ISO 9001:2015 Certified Laboratory.